News Releases

Date Title and Summary Additional Formats
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , June 05, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Participate at BIO International Convention 2019
-- Company to Provide Insight on Key CDMO Industry Topics through Podium Presentation, Panel Discussion and Executive Interview as Part of Convention’s BioProcess  International Theater -- -- Corporate Booth to Highlight Company’s CDMO Service Offerings and State-of-the-Art Clinical and Commercial
View HTML
Toggle Summary Avid Bioservices Reaffirms Fiscal 2019 Guidance and Announces Upcoming Conference Participation
TUSTIN, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology
View HTML
Toggle Summary Avid Bioservices Names Richard B. Hancock as Interim President and Chief Executive Officer
Industry Veteran with Over 30 Years of Operational and Executive Experience Succeeds Roger J. Lias, Ph.D. TUSTIN, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working
View HTML
Toggle Summary Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2019 and Recent Developments
-- Achieved Revenue of $13.8 Million , an Increase of 102% Compared to Prior Year Quarter -- -- Signed Project Expansion Orders with Existing Customers Representing $23.8 Million -- -- Completed Process Validation Campaign for Future Commercial Production with Other Validations Ongoing -- TUSTIN,
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices To Report Financial Results For Third Quarter Of Fiscal Year 2019 After Market Close On March 11, 2019
TUSTIN, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2019 and Recent Developments
-- F iscal 2019 Projected Revenue of $51 to $55 Million Reaffirmed -- -- Signed Project Expansion Orders for $6.3 Million with Current Customers -- -- Successfully Executed Scheduled Broad Scale Facilities Maintenance and Upgrade Program -- TUSTIN, Calif. , Dec.
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2019 After Market Close on December 10, 2018
TUSTIN, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Exhibit at the 17th Annual Contracting & Outsourcing Conference
-- Participation at One-Day Tabletop Exhibition to Include Virtual Tour of Myford Late-Stage Clinical and Commercial Biomanufacturing Facility Highlighting Immediately Available 2,000-Liter Scale Bioreactor Capacity -- TUSTIN, Calif. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc.
View HTML
Toggle Summary Avid Bioservices Reports Financial Results for First Quarter Fiscal 2019 and Recent Developments
-- F iscal 2019 Projected Revenue of $51 to $55 Million Reaffirmed -- -- Multiple Projects Advanced During the Quarter -- -- Initiated Operations of New Process Development Laboratories -- TUSTIN, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc.
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2019 After Market Close on September 10, 2018
TUSTIN, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Present at Upcoming Investor Conferences
TUSTIN, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology
View HTML